<!DOCTYPE html>
<html>
<meta charset="UTF-8">
<head>
    <title>HLA-B——KIR3DL1 - PMID Details</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
            color: #333;
        }

        h1 {
            text-align: center;
            font-size: 2.5em;
            color: #2c3e50;
            margin-bottom: 20px;
        }

        /* Navbar Styles */
        nav {
            background-color: #2c3e50;
            padding: 10px 20px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            color: white;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        nav .navbar-left, nav .navbar-right {
            display: flex;
            align-items: center;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin: 0 15px;
            font-size: 1.1em;
            transition: color 0.3s ease;
        }

        nav a:hover {
            color: #f39c12;
        }

        nav .divider {
            color: #ecf0f1;
            margin: 0 10px;
        }

        /* Page Footer */
        footer {
            margin-top: 40px;
            padding: 10px 20px;
            background-color: #f7f7f7;
            color: #333;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        /* Tab and Content Styles */
        .tab {
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            margin-bottom: 20px;
        }

        .tab button {
            padding: 10px 20px;
            margin: 5px;
            margin-bottom: 10px;
            cursor: pointer;
            background-color: #f4f4f4;
            border: 2px solid #ddd;
            border-radius: 5px;
            font-size: 1.1em;
            transition: background-color 0.3s ease;
            flex-basis: calc(10% - 10px);
            box-sizing: border-box;
        }

        .tab button:hover {
            background-color: #ecf0f1;
        }

        .tab button.active {
            background-color: #3498db;
            color: white;
            border-color: #2980b9;
        }

        .tabcontent {
            display: none;
            padding: 20px;
            margin-top: 10px;
            background-color: #ecf0f1;
            border-radius: 5px;
            box-shadow: 0px 0px 10px rgba(0, 0, 0, 0.1);
        }

        .tabcontent.active {
            display: block;
        }

        .tabcontent h2 {
            font-size: 2em;
            color: #2980b9;
        }

        .tabcontent p {
            font-size: 1.2em;
            line-height: 1.8;
        }

        /* Emphasize Title and Abstract */
        .title, .abstract {
            background-color: #f9f9f9;
            padding: 20px;
            margin: 10px 0;
            border-left: 5px solid #2980b9;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }

        .abstract {
            border-left: 5px solid #e74c3c;
        }
    </style>
    <script>
        function adjustTabStyle() {
            var tabCount = document.querySelectorAll('.tab button').length;
            var tabContainer = document.querySelector('.tab');

            if (tabCount > 10) {
                tabContainer.classList.add('small-tabs');
            }
        }

        function openTab(evt, tabId) {
            document.querySelectorAll(".tabcontent").forEach(tab => tab.style.display = "none");
            document.querySelectorAll(".tablinks").forEach(link => link.classList.remove("active"));
            document.getElementById(tabId).style.display = "block";
            evt.currentTarget.classList.add("active");
        }

        window.onload = adjustTabStyle;
    </script>
</head>
<body>
    <nav>
        <div class="navbar-left">
            <a href="">ConnectomeDB</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/">Home</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/database.html">Database</a>
        </div>
        <div class="navbar-right">
            <a href="https://www-user.yokohama-cu.ac.jp/~bioinfo/">YCU Bioinformatics Lab</a>
            <span class="divider">|</span>
            <a href="https://perkins.org.au/research/labs/cancer-program/systems-biology-and-genomics-overview/">Perkins Systems Biology & Genomics Lab</a>
        </div>
    </nav>

    <h1>PMID Details for HLA-B——KIR3DL1</h1>

    <div class="tab">
        <button class="tablinks active" onclick="openTab(event, 'tab15607823')">15607823</button><button class="tablinks " onclick="openTab(event, 'tab8046332')">8046332</button>
    </div>

    <div class="tabcontent" id="titleTab">
        <div class="title">
            <h2>Title</h2>
            <p>{{TITLE}}</p>
            <i> Journal:{{JOURNAL}}; Year Published:{{YEAR}}</i>   
        </div>
    </div>

    <div class="tabcontent" id="abstractTab">
        <div class="abstract">
            <h2>Abstract</h2>
            <p>{{ABSTRACT}}</p>
        </div>
    </div>

    
                <div id="tab15607823" class="tabcontent active">
                    <h2>A HLA-Cw6 specific single-chain antibody fragment (scFv) recognizing a natural killer cell receptor epitope.</h2>
                    <h3>Molecular immunology; 2005</h3>
                    <p>Major histocompatibility complex (MHC) class I molecules induce inhibitory signals on natural killer (NK) cells via killer cell immunoglobulin-like receptors (KIR). We recently reported a human single-chain antibody (scFv#1), which recognizes an epitope on HLA-Cw6 (genotype: *0602). Flow cytometry showed scFv#1 binding to HLA-Cw6 (strong) and also to HLA-Cw2, 4, 5 (very weak) but not to HLA-Cw1, 3, 7, 8. The presumptive epitope of the antibody fragment, which includes residues Asn77 and Lys80 was verified by introducing point mutations into HLA-Cw6 encoding cDNAs. Asn77 --> Ser77 (N77S) and Lys80- -> Asn80 (K80N) mutants of Cw6 lost scFv#1 binding capacity whereas an additional mutation at aa position 90 (Asp-->Ala, D90A) did not influence scFv#1 binding characteristics. Since residues 77 and 80 of HLA-C are directly involved in KIR/MHC interaction, we expected the induction of target cell lysis upon addition of scFv#1 when bringing NK and HLA-Cw6 positive cells together. To prove this interference, we performed Cr-release assays, using Cw*0602 and mock-transfected K562 erythroleukemia cells as targets and freshly prepared peripheral blood NK cells as effector cells. scFv#1 appeared to influence KIR on ligand binding and restored lysis at low effector to target (E/T) ratios. Pan HLA class I antibody W6/32 did not show such effects. Taken together scFv#1 binding patterns with mutagenized HLA-Cw6 and Cr-release assays are strong evidence that the scFv#1 epitope on HLA-Cw6 is at or close to the binding site of CD158a.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/15607823/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab8046332" class="tabcontent ">
                    <h2>NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules.</h2>
                    <h3>The Journal of experimental medicine; 1994</h3>
                    <p>Natural killer (NK) cells kill normal and transformed hematopoietic cells that lack expression of major histocompatibility complex (MHC) class I antigens. Lysis of HLA-negative Epstein Barr virus-transformed B lymphoblastoid cell lines (B-LCL) by human NK cell clones can be inhibited by transfection of the target cells with certain HLA-A, -B, or -C alleles. NK cell clones established from an individual demonstrate clonal heterogeneity in HLA recognition and a single NK clone can recognize multiple alleles. We describe a potential human NK cell receptor (NKB1) for certain HLA-B alleles (e.g., HLA-B*5101 and-B*5801) identified by the mAb DX9. NKB1 is a 70-kD glycoprotein that is expressed on a subset of NK cells and NK cell clones. DX9 monoclonal antibody (mAb) specifically inhibits the interaction between NK cell clones and B-LCL targets transfected with certain HLA-B alleles, but does not affect recognition of HLA-A or HLA-C antigens. An individual NK cell clone can independently recognize B-LCL targets transfected with HLA-B or HLA-C antigens; however, DX9 mAb only affects interaction with transfectants expressing certain HLA-B alleles. These findings demonstrate the existence of NK cell receptors involved in the recognition of HLA-B and imply the presence of multiple receptors for MHC on an individual NK clone.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/8046332/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                

    <footer>
        <span>© Copyright 2024, YCU Bioinformatics Laboratory</span>
        <span>Page built with <a href="https://quarto.org/">Quarto</a> by バイオインフォマティクス解析センター</span>
    </footer>
</body>
</html>
